Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3101 in Advanced Malignancies With Oncogenic Kinase Alterations
CTR20200698Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of unecritinib in Non-hematologic malignancy, hematopoietic malignancies, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2020; status: completed.
02
Drugs
unecritinib
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on CTR20200698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200698.